| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 30/04/2019 | 13:00 | GlobeNewswire Inc. | ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 12/03/2019 | 21:01 | GlobeNewswire Inc. | Harrow Health Announces Fourth Quarter 2018 Financial Results | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 04/03/2019 | 13:00 | GlobeNewswire Inc. | Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 28/02/2019 | 13:00 | GlobeNewswire Inc. | Harrow Health to Announce Fourth Quarter 2018 Financial Results on March 12, 2019 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 13/02/2019 | 13:00 | GlobeNewswire Inc. | Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 07/02/2019 | 13:00 | GlobeNewswire Inc. | Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 05/02/2019 | 13:00 | GlobeNewswire Inc. | Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 03/01/2019 | 23:27 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 31/12/2018 | 13:01 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 31/12/2018 | 13:00 | GlobeNewswire Inc. | Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc. | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 16/11/2018 | 13:30 | GlobeNewswire Inc. | Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™ | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 13/11/2018 | 22:22 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 13/11/2018 | 22:01 | GlobeNewswire Inc. | Imprimis Pharmaceuticals Announces Third Quarter 2018 Results | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 06/11/2018 | 13:00 | GlobeNewswire Inc. | Imprimis Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 13, 2018 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 23/10/2018 | 13:00 | GlobeNewswire Inc. | Imprimis Pharmaceuticals’ Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioi... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 16/10/2018 | 13:00 | GlobeNewswire Inc. | ImprimisRx to feature new formulation and poster presentation on MKO Melt® at the upcoming American Academy of Ophthalmology... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 07/09/2018 | 23:33 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 06/08/2018 | 22:01 | PR Newswire (US) | Imprimis Pharmaceuticals Announces Second Quarter 2018 Results | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 01/08/2018 | 13:30 | PR Newswire (US) | Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi™ (Triamcinolone Acetonide-Moxifloxacin for injection)... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 31/07/2018 | 13:30 | GlobeNewswire Inc. | Imprimis Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 6, 2018 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 18/07/2018 | 13:30 | PR Newswire (US) | Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 30/05/2018 | 13:30 | PR Newswire (US) | ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Ref... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 15/05/2018 | 22:01 | PR Newswire (US) | Imprimis Pharmaceuticals Announces First Quarter 2018 Results | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 15/05/2018 | 13:30 | PR Newswire (US) | Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 02/05/2018 | 13:30 | GlobeNewswire Inc. | Imprimis Pharmaceuticals to Host its First Quarter 2018 Financial Report Conference Call and Webcast on May 15, 2018 at 4:30 ... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 01/05/2018 | 00:28 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 12/04/2018 | 22:39 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 10/04/2018 | 13:30 | PR Newswire (US) | Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (m... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 27/03/2018 | 13:30 | PR Newswire (US) | Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 08/03/2018 | 22:31 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |